Latest Post

September 18, 2019no comments

Cellular social networks give cancer cells a cloak of invincibility

Ever since DrugBaron studied biochemistry at the end of the 1980s, one question about cancer has always perplexed him: why can we induce almost complete remission and yet the cancer can come back stronger and invariably kill the patient?  The answer now, as then, has always been selection of the rare, resistant mutant.

 

But DrugBaron was always left with a nagging doubt.  Two observations seemed to call that obvious and simple answer into question.

 

Read More

Tweets

@MaverickNY Thanks. Appreciate the encouragement. I enjoyed doing it so much, I’m sure it won’t be long before I pi… https://t.co/1nuwKiapxt
- Thursday Oct 17 - 8:46pm

@AAMortazavi @jimcramer Yep. It’s beef-on-the-bone and vCJD all over again. Four deaths at the Hatfield rail crash… https://t.co/jGvccWVlsl
- Thursday Oct 17 - 8:02pm

SCIENTIFIC SUPPOSITIONS

Contact DrugBaron and Subscribe for a weekly digest of new postsNews, musings & opinions from the pen of the Drug Baron, Cambridge

Drug Baron Blog

Latest Post

September 18, 2019 no comments

Cellular social networks give cancer cells a cloak of invincibility

Ever since DrugBaron studied biochemistry at the end of the 1980s, one question about cancer has always perplexed him: why can we induce almost complete remission and yet the cancer can come back stronger and invariably kill the patient?  The answer now, as then, has always been selection of the rare, resistant mutant.

 

But DrugBaron was always left with a nagging doubt.  Two observations seemed to call that obvious and simple answer into question.

 

Firstly, for the most part that is not what we see with infectious agents.  Even viruses, which share with cancer cells a short generation time and a ready ability to mutate, can usually be cured as long as you hit them hard – because the chances of a resistant variant existing in the population is quite low.  As long as you don’t give them time to find one over many generations, you can eliminate the infection.  Since tumours typically have a much smaller cell population size than an infection, it follows that cancer should be easier to cure than it is.

 

Secondly, some cancers, such as some leukemias can be cured almost every time, while others, such as the brain cancer glioblastoma, are almost invariably lethal.  Yet there is no obvious association between mutation rate or the cancer cell population size and tractability of the cancer type.

 

It’s hard to put a finger on it, but it has always felt like a key part of the puzzle was missing.

 

And then, a few years ago, DrugBaron was sitting in a bar in Cambridge, UK, enjoying a drink with my friend and colleague Professor Miro Radman, when in the space of an hour he suggested to me exactly why some tumours were essentially invincible.  The missing piece, it turned out, was the ability of cells to form networks.

 

For sure, I was aware that cells often formed connections with each other.  Indeed, skeletal muscle is made up of giant syncytia formed by the complete fusion of many individual cells that give up their autonomy to work together.  In other tissues, the cells remain separate but communicate through numerous channels, such as the gap junctions between cardiac cells that ensure the contraction during a heartbeat is carefully co-ordinated.  But, like most people, DrugBaron had never considered the full implications of such cell networks before – and certainly never imagined they had anything to do with cancer.

 

Prof Radman’s concept was logical enough: if cells are highly connected, then they cannot change phenotype very easily.  Rather like a snake with two heads, if one wants to go left and the other right, it will continue down the middle.  In the same way, networks of cells ensure phenotypic stability in normal tissues.  For any cell …

More

Yearly Archive

Useful Resources

Discovering and developing drugs according to the “asset-centric” strategy depends entirely on the availability of high quality out-sourced service providers, who not only deliver the R&D infra-structure for small and virtual biotech companies, but who understand the essential differences between “asset-centric” R&D and the classical model. DrugBaron has founded and worked for more than a dozen asset-centric companies over the last decade, developing both small molecules and biologics in a wide range of indications. That experience has identified those service providers (usually smaller than the global brands) who understand “asset-centric” R&D and who can support new companies adopting this strategy.  Those are the companies listed here.

The Cambridge Partnership is the only professional services company in the UK exclusively dedicated to supporting companies in the biotechnology industry. We specialize in providing a “one-stop shop” for accountancy, company secretarial, IP management and admin services.

Accounting & Back-Office Services

A professional services company exclusively dedicated to supporting companies within the biotechnology industry.

RxCelerate Ltd is an outsourced drug development platform based near Cambridge, UK. We specialize in delivering an entire road map of drug development services from discovery and medicinal chemistry through to preclinical and clinical Phase IIa.

Out Sourced Drug Developer

Specialising in delivering an entire road map of drug development services from discovery through to preclinical/clinical Phase IIa.

SEND & SUBSCRIBE

Contact DrugBaron and Subscribe for a weekly digest of new posts

Contact Us

EMAIL
drugbaron@rxcelerate.com

RxCelerate UK
Babraham Research Campus
Babraham
Cambridge CB22 3AT
United Kingdom